MULTIFACTORIAL METHODS FOR DETECTING LUNG DISORDERS
Described herein are multifactorial methods for detecting, diagnosing or aiding in the diagnosis of lung disorders or disease, e.g., lung cancer. The methods disclosed utilize multiple diagnostic paradigms, for example, to improve diagnostic sensitivity, specificity, negative predictive value and/or positive predictive value over each of the paradigms alone. For example, a clinicogenomic model is disclosed for lung cancer diagnosis which combines clinical factors and gene expression, particularly a sensitive and specific gene expression biomarker.
1 . A method of aiding in the diagnosis of lung disease in a patient suspected of having lung disease, comprising:
analyzing two or more independent lung cancer-relevant diagnostic paradigms in a patient to be assessed; and
determining a composite classification of the patient as having lung disease or not having lung disease.
2 . A method according to claim 1 wherein the lung disease is lung cancer.
3 . A method according to claim 1 wherein the patient is a smoker or former smoker.
4 . A method according to claim 1 wherein the patient has had an abnormal radiographic finding or a nondiagnostic bronchoscopy.
5 . A method according to claim 1 wherein the two or more lung cancer-relevant diagnostic paradigms are selected from the group consisting of analyzing expression of one or more lung cancer-relevant genes in the patient, analyzing one or more lung cancer-relevant clinical factors or variables of the patient, testing for the presence or absence of one or more lung cancer-relevant antibodies in the patient's blood, testing for the presence or absence of one or more lung cancer-relevant proteins in the patient's blood, and analyzing expression of one or more lung cancer-relevant microPNAs.
6 . A method according to claim 1 wherein the two or more lung cancer-relevant diagnostic paradigms comprise analyzing expression of one or more lung cancer-relevant genes in the patient.
7 . A method according to claim 1 wherein the two or more lung cancer-relevant diagnostic paradigms comprise analyzing expression of one or more lung cancer-relevant genes in the patient and one or more lung cancer-relevant diagnostic paradigms selected from the group consisting of analyzing one or more lung cancer-relevant clinical factors or variables of the patient, testing for the presence or absence of one or more lung cancer-relevant antibodies in the patient's blood, testing for the presence or absence of one or more lung cancer-relevant proteins in the patient's blood, and analyzing expression of one or more lung cancer-relevant microRNAs.
8 . A method according to claim 6 wherein the one or more lung cancer-relevant genes are all or a subset of the genes for which expression data is contained in Gene Expression Omnibus accession no GSE4115.
9 . A method according to claim 7 wherein the one or more lung cancer-relevant genes are all or a subset of the genes for which expression data is contained in Gene Expression Omnibus accession no. GSE4115.
10 . A method according to claim 1 wherein the two or more lung cancer-relevant diagnostic paradigms comprise analyzing expression of one or more lung cancer-relevant genes in the patient and analyzing one or more lung cancer-relevant clinical factors or variables of the patient.
11 . A method according to claim 10 wherein the one or more lung cancer-relevant genes are all or a subset of the genes for which expression data is contained in Gene Expression Omnibus accession no. GSE4115.
12 . A method of determining a follow up treatment regimen for a patient suspected of having lung cancer, comprising
analyzing two or more independent lung cancer-relevant diagnostic paradigms in a patient to be assessed, and classifying the patient as having cancer or not having cancer on the basis of the analysis,
wherein a patient classified as having cancer is selected for invasive testing and/or commencement of therapeutic regimen, and a patient classified as not having cancer is monitored without invasive testing or commencement of therapeutic regimen.
13 . A method according to claim 12 wherein the patient is a smoker or former smoker.
14 . A method according to claim 12 wherein the patient has had an abnormal radiographic finding or a nondiagnostic bronchoscopy.
15 . A method according to claim 12 wherein the two or more lung cancer-relevant diagnostic paradigms are selected from the group consisting of analyzing expression of one or more lung cancer-relevant genes in the patient, analyzing one or more lung cancer-relevant clinical factors or variables of the patient, testing for the presence or absence of one or more lung cancer-relevant antibodies in the patient's blood, testing for the presence or absence of one or more lung cancer-relevant proteins in the patient's blood, and analyzing expression of one or more lung cancer-relevant microRNAs.
16 . A method according to claim 12 wherein the two or more lung cancer-relevant diagnostic paradigms comprise analyzing expression of one or more lung cancer-relevant genes in the patient.
17 . A method according to claim 12 wherein the two or more lung cancer-relevant diagnostic paradigms comprise analyzing expression of one or more lung cancer-relevant genes in the patient and one or more lung cancer-relevant diagnostic paradigms selected from the group consisting of analyzing one or more lung cancer-relevant clinical factors or variables of the patient, testing for the presence or absence of one or more lung cancer-relevant antibodies in the patient's blood, testing for the presence or absence of one or more lung cancer-relevant proteins in the patient's blood, and analyzing expression of one or more lung cancer-relevant microRNAs.
18 . A method according to claim 16 wherein the one or more lung cancer-relevant genes are all or a subset of the genes for which expression data is contained in Gene Expression Omnibus accession no. GSE4115.
19 . A method according to claim 12 wherein the two or more lung cancer-relevant diagnostic paradigms comprise analyzing expression of one or more lung cancer-relevant genes in the patient and analyzing one or more lung cancer-relevant clinical factors or variables of the patient.
20 . A method of aiding in the diagnosis of lung cancer in a patient suspected of having lung cancer, comprising:
obtaining a biological sample from the patient and analyzing expression of one or more lung cancer-relevant genes in the sample, wherein the one or more lung cancer-relevant genes are all or a subset of the genes for which expression data is contained in Gene Expression Omnibus accession no. GSE4115;
analyzing one or more lung cancer-relevant clinical factors or variables of the patient; and
determining a composite classification of the patient as having cancer or not having cancer.